Answer
Women should not breastfeed during treatment with Mylotarg (gemtuzumab ozogamicin) and for at least one month after the final dose because of potential adverse drug reactions in breastfed children.
Sources for this answer
- MYLOTARG 5mg powder for concentrate for solution for infusionPfizer Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 13Document updated
Sources checked